Compare WINA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | MRVI |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2006 | 2020 |
| Metric | WINA | MRVI |
|---|---|---|
| Price | $279.06 | $7.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 60.4K | ★ 2.3M |
| Earning Date | 10-14-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 3.76 | ★ 14.29 |
| EPS | ★ 8.51 | N/A |
| Revenue | $86,055,700.00 | ★ $185,743,000.00 |
| Revenue This Year | $12.61 | $14.01 |
| Revenue Next Year | $44.75 | $6.20 |
| P/E Ratio | $33.48 | ★ N/A |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $279.42 | $2.55 |
| 52 Week High | $488.83 | $9.42 |
| Indicator | WINA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 37.94 | 50.65 |
| Support Level | N/A | $6.41 |
| Resistance Level | $311.29 | $7.60 |
| Average True Range (ATR) | 11.93 | 0.51 |
| MACD | -0.58 | -0.01 |
| Stochastic Oscillator | 6.83 | 39.53 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment, including Franchising, and one non-reportable segment, Leasing. The franchising segment franchises value-oriented retail stores that buy, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes the middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.